<?xml version="1.0" encoding="UTF-8"?>
<p>Another clinical trial aiming to test with the use of hyperbaric oxygen was estimated to start on 25 April 2020. The anti-inflammatory effects, which include decreased expression of IL-1β, IL-6 and TNF-α [
 <xref rid="B136-jcm-09-01917" ref-type="bibr">136</xref>,
 <xref rid="B137-jcm-09-01917" ref-type="bibr">137</xref>], could be beneficial to mitigate ARDS associated with COVID-19 and fibrosis development.
</p>
